Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 10513 - 10520 of 12011 results
Making “Material Adverse Change” Mean What You Choose It to Mean — Neither More nor Less
April 9, 2014| Alert| Viewpoint
CMS Issues Final Call Letter for 2015
April 9, 2014| Blog| Viewpoint
SEC Steps Up Scrutiny of Municipal Bonds: Recently Filed Enforcement Actions
April 9, 2014| Blog| Viewpoint
Negligent Disclosure and Imputed Scienter: Recent SEC Enforcement Actions Against Municipal Bond Issuers
April 9, 2014| Blog| Viewpoint
Clean Edge 2014 Clean Energy Trends Report: Key Trends Emerging from 2013
April 8, 2014| Blog| Viewpoint
Supreme Court Rewrites the Rules for Individual Campaign Contributions: McCutcheon v. Federal Election Commission
April 8, 2014| Alert| Viewpoint
Law360′s “Exxon Opens a New Disclosure Frontier for Energy Finance”
April 8, 2014| Blog| Viewpoint
New Draft Processor to Sub-processor Model Clauses (Art. 29 Working Party)
April 8, 2014| Blog| Viewpoint
News & Press Releases
Mintz advised The Eagle Leasing Company, a leading provider of portable storage containers, ground level offices, semi-trailers, and mobile office solutions, in its acquisition by Rent-A-Container (RAC), a portfolio company of Kinderhook Industries, LLC.
Mintz’s Life Sciences practice has been shortlisted in multiple categories for the 2025 LMG Life Sciences Americas Awards. The winners will be announced at an awards ceremony in New York on September 4. In the United States, Mintz was shortlisted in the “Venture Capital Firm of the Year” category. In Canada, Mintz was shortlisted in the “Financial & Corporate Firm of the Year” and “Patent Strategy Firm of the Year” categories.
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|